CANbridge Pharmaceuticals Inc. (SEHK: 1228)
Health Care · Biotechnology · CN
HK$2.03
-10.77% today · +0.5% 1Y
CANbridge Pharmaceuticals Inc. (SEHK: 1228) operates in the Biotechnology industry within the Health Care sector. The company is valued at $154.03M and employs 41 people.
Over the last twelve months the share price has gained 0.5%, trading between 1.61 and 3.50.
Tweenvest scores CANbridge Pharmaceuticals Inc. across four factors: quality 19/100, value 60/100, growth 65/100. Its strongest factor is growth.
1228 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $154.03M
- Revenue (TTM)
- $7.15M
- P/E
- 60.81
- EPS
- 0.03
- Dividend yield
- —
- Beta (5Y)
- -0.12
- 52-week high
- HK$3.50
- 52-week low
- HK$1.61
- Avg volume (3M)
- —
- Shares outstanding
- 595.44M
- Employees
- 41
- Next earnings
- —
About CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on the global research, development, and commercialization of treatments for rare disorders and various cancer types. The company's marketed products include Hunterase, an enzyme replacement therapy for Hunter syndrome; NERLYNX (Neratinlib), a powerful, irreversible tyrosine kinase inhibitor targeting HER2-positive breast cancer; and Caphosol Mouth Rinse, used to alleviate temporary and persistent dry mouth and throat. Its robust development pipeline features several investigational therapies: CAN008, an artificially engineered antibody-like fully human fusion protein being developed for glioblastoma multiforme; CAN108, an orally administered reversible inhibitor of the ileal bile acid transporter, designed to treat rare cholestatic liver diseases; CAN106, a humanized monoclonal antibody against complement C5 for complement-mediated conditions; CAN103 and CAN104, both recombinant human enzyme replacement therapies (ERTs); CAN105, a bispecific antibody; and gene therapy programs CAN201 and CAN202, both utilizing adeno-associated virus (AAV) sL65 capsid technology. Established in 2012, CANbridge Pharmaceuticals Inc. is based in Beijing, China.
- ISIN
- KYG1821D1097
- Founded
- 2012
- Listed since
- Dec 10, 2021
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.